Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGE031 in uncontrolled asthma on ICS/LABA
NL-OMON42235Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ligelizumab in asthma (4 arms), sponsored by Novartis. Primary endpoint: Rate of severe asthma exacerbations during 52 weeks of treatment. Started Nov 2015; status: active, not recruiting.
02
Drugs
ligelizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON42235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42235.